Futibatinib for intrahepatic cholangiocarcinoma

被引：0
|
作者：
Baker, Holly
机构：
来源：
LANCET GASTROENTEROLOGY & HEPATOLOGY | 2023年 / 8卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：304 / 304
页数：1
相关论文
共 50 条
  • [1] Oral futibatinib in intrahepatic cholangiocarcinoma
    Lorenz, Judith
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2023, 61 (07): : 775 - 775
  • [2] Futibatinib: new targeted therapy in intrahepatic cholangiocarcinoma
    Khoury, Rita
    Khalife, Nadine
    Ibrahim, Rebecca
    Saleh, Khalil
    HEPATOBILIARY SURGERY AND NUTRITION, 2023, 12 (06) : 923 - 926
  • [3] Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma
    Goyal, Lipika
    Meric-Bernstam, Funda
    Hollebecque, Antoine
    Valle, Juan W.
    Morizane, Chigusa
    Karasic, Thomas B.
    Abrams, Thomas A.
    Furuse, Junji
    Kelley, Robin K.
    Cassier, Philippe A.
    Kluempen, Heinz-Josef
    Chang, Heung-Moon
    Chen, Li-Tzong
    Tabernero, Josep
    Oh, Do-Youn
    Mahipal, Amit
    Moehler, Markus
    Mitchell, Edith P.
    Komatsu, Yoshito
    Masuda, Kunihiro
    Ahn, Daniel
    Epstein, Robert S.
    Halim, Abdel-Baset
    Fu, Yao
    Salimi, Tehseen
    Wacheck, Volker
    He, Yaohua
    Liu, Mei
    Benhadji, Karim A.
    Bridgewater, John A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (03): : 228 - 239
  • [4] Futibatinib: paving the way to personalized medicine in intrahepatic cholangiocarcinoma
    Khoury, Rita
    Chahine, Claude
    Ibrahim, Rebecca
    Khalife, Nadine
    Saleh, Mohammad
    Saleh, Khalil
    FUTURE ONCOLOGY, 2023, 19 (17) : 1161 - 1163
  • [5] Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives
    Rizzo, Alessandro
    Ricci, Angela Dalia
    Brandi, Giovanni
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2021, 30 (04) : 317 - 324
  • [6] Futibatinib (Lytgobi) for cholangiocarcinoma
    Roskoski Jr, Robert
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2023, 44 (03) : 190 - 191
  • [7] Pooled analysis safety profile of futibatinib in patients with advanced solid tumors, including intrahepatic cholangiocarcinoma (iCCA)
    Meric-Bernstam, F.
    Furuse, J.
    Oh, D-Y.
    Bridgewater, J. A.
    Goyal, L.
    Bahleda, R.
    Li, K.
    Patel, P.
    Soni, N.
    Wacheck, V.
    Moehler, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S378 - S378
  • [8] Clinical response to futibatinib in intrahepatic cholangiocarcinoma with acquired resistance to fibroblast growth factor receptor 2 inhibitors
    Casalino, S.
    Gerdes, C.
    Saborowski, A.
    Quinzii, A.
    Zecchetto, C.
    Sordo, A.
    Messineo, L.
    Leta, L. C.
    Lucin, E.
    Mendo, L.
    Pietrobono, S.
    Vogel, A.
    Melisi, D.
    ANNALS OF ONCOLOGY, 2024, 35 : S128 - S129
  • [9] Futibatinib: A Review in Locally Advanced and Metastatic Cholangiocarcinoma
    Hoy, Sheridan M.
    TARGETED ONCOLOGY, 2024, 19 (03) : 473 - 480
  • [10] Futibatinib for intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements: Japanese sub-analysis of FOENIXCCA2
    Morizane, Chigusa
    Komatsu, Yoshito
    Masuda, Kunihiro
    Kanai, Masashi
    Ioka, Tatsuya
    Ueno, Makoto
    Ozaka, Masato
    Mizuno, Takashi
    Sakai, Daisuke
    Nakamura, Masafumi
    Shimura, Masashi
    Lipika, Goyal
    Furuse, Junji
    ANNALS OF ONCOLOGY, 2023, 34 : S1380 - S1380
12345